<DOC>
	<DOCNO>NCT01868997</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability effectiveness fully human antibody compare placebo treatment patient active thyroid eye disease . `` Funding Source - FDA OOPD ''</brief_summary>
	<brief_title>Teprotumumab Treatment Patients With Active Thyroid Eye Disease</brief_title>
	<detailed_description>A multicenter , double-masked , placebo-controlled , efficacy safety study RV 001 , insulin-like growth factor-1 receptor ( IGF-1R ) antagonist antibody ( fully human ) , administer every 3 week ( q3W ) intravenous ( iv ) infusion patient suffer active thyroid eye disease ( TED )</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Graves Ophthalmopathy</mesh_term>
	<criteria>Clinical diagnosis Graves'disease associate active thyroid eye disease clinical activity score &gt; 4 Fewer 9 month onset thyroid eye disease No previous medical surgical treatment , exclude local supportive measure steroid maximum cumulative dose less 1000 mg methylprednisolone equivalent least 6 week last administration steroid randomization Euthyroid mild hypo hyperthyroidism define free thyroxine ( FT4 ) free triiodothyronine ( FT3 ) level less 50 % normal limit . Every effort make correct mild hypo hyperthyroidism promptly . Optic neuropathy Corneal decompensation unresponsive medical management Oral IV steroid treatment reason precede 3 month Poorly control diabetes Platelets &lt; 100 x 109/L Hemoglobin concentration &gt; 2gr/dl low limit normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Thyroid Eye Disease , Graves Orbitopathy , Thyroid Associated</keyword>
	<keyword>Ophthalmopathy</keyword>
</DOC>